Medicine | Oncology
Prostate cancer
Treatment | Deferred treatment
Active surveillance

Home > Disciplines > Medicine > Oncology > Prostate cancer > Treatment > Deferred treatment > Active surveillance

Contents

Overview

.

Briganti A, Fossati N, Catto JWF, Cornford P, Montorsi F, Mottet N, Wirth M, Van Poppel H.
Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018.
Eur Urol. 2018 Jun 21. pii: S0302-2838(18)30433-0. doi: 10.1016/j.eururo.2018.06.008. [Epub ahead of print]
Source | Full text | Similar articles

.

Caliskan S, Keles MO, Kaba S, Koca O, Akyuz M, Ozturk MI, Karaman MI.
Active surveillance or radical prostatectomy? Which treatment is best?
Bratisl Lek Listy. 2016;117(8):468-71. Epub 2016 Aug 10.
Source | Full text | Similar articles

.

de Carvalho TM, Heijnsdijk EAM, de Koning HJ.
When should active surveillance for prostate cancer stop if no progression is detected?
Prostate. 2017 Apr 17. doi: 10.1002/pros.23352. [Epub ahead of print]
Source | Full text | Similar articles

.

Ehdaie B.
Active surveillance for prostate cancer: is it too active?
BJU Int. 2016 Sep;118(3):343. doi: 10.1111/bju.13473.
Source | Full text | Similar articles

.

Herden J, Weissbach L.
Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
World J Urol. 2018 Jan 12. doi: 10.1007/s00345-018-2175-0. [Epub ahead of print]
Source | Full text | Similar articles

.

Garisto JD, Klotz L.
Active Surveillance for Prostate Cancer: How to Do It Right.
Oncology (Williston Park). 2017 May 15;31(5):333-40, 345.
Source | Full text | Similar articles

.

Klotz L.
Contemporary approach to active surveillance for favorable risk prostate cancer.
Asian J Urol. 2019 Apr;6(2):146-152. doi: 10.1016/j.ajur.2018.12.003. Epub 2018 Dec 15.
Source | Full text | Similar articles

.

Klotz L.
Contemporary Active Surveillance: Candidate Selection, Follow-up Tools, and Expected Outcomes.
Urol Clin North Am. 2017 Nov;44(4):565-574. doi: 10.1016/j.ucl.2017.07.005.
Source | Full text | Similar articles

.

Klotz L.
Active surveillance for prostate cancer: overview and update.
Curr Treat Options Oncol. 2013 Mar;14(1):97-108. doi: 10.1007/s11864-012-0221-5. First Online: 15 January 2013.
Source | Full text | Similar articles

.

Klotz L (ed).
Active Surveillance for Localized Prostate Cancer: A New Paradigm for Clinical Management.
Humana Press, 2012 (Book, 208 pages)
Source | Abstract | Full text

.

Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A.
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
J Clin Oncol. 2010 Jan 1;28(1):126-31. doi: 10.1200/JCO.2009.24.2180. Epub 2009 Nov 16.
Source | Full text | Similar articles

Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH, Bjartell A, Bossi A, Briers E, Briganti A, Buddingh KT, Catto JWF, Colecchia M, Cox BW, Cumberbatch MG, Davies J, Davis NF, De Santis M, Dell'Oglio P, Deschamps A, Donaldson JF, Egawa S, Fankhauser CD, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Gross T, Grummet JP, Henry AM, Ingels A, Irani J, Lardas M, Liew M, Lin DW, Moris L, Omar MI, Pang KH, Paterson CC, Renard-Penna R, Ribal MJ, Roobol MJ, Rouprêt M, Rouvière O, Sancho Pardo G, Richenberg J, Schoots IG, Sedelaar JPM, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, van Leenders GJLH, Varma M, Violette PD, Wallis CJD, Wiegel T, Wilkinson K, Zattoni F, N'Dow JMO, Van Poppel H, Cornford P, Mottet N.
EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study).
Eur Urol. 2019 Dec;76(6):790-813. doi: 10.1016/j.eururo.2019.09.020. Epub 2019 Oct 3.
Source . Similar articles

.

Marenghi C, Alvisi MF, Palorini F, Avuzzi B, Badenchini F, Bedini N, Bellardita L, Biasoni D, Bosetti D, Casale A, Catanzaro M, Colecchia M, De Luca L, Donegani S, Dordoni P, Lanocita R, Maffezzini M, Magnani T, Menichetti J, Messina A, Morlino S, Paolini B, Rancati T, Stagni S, Tesone A, Torelli T, Tulli Baldoin E, Vaiani M, Villa S, Villa S, Zaffaroni N, Nicolai N, Salvioni R, Valdagni R.
Eleven-year management of prostate cancer patients on active surveillance: what have we learned?
Tumori. 2017 Jun 14:0. doi: 10.5301/tj.5000649. [Epub ahead of print]
Source | Full text | Similar articles

.

Matulewicz RS, Weiner AB, Schaeffer EM.
Active Surveillance for Prostate Cancer.
JAMA. 2017 Dec 5;318(21):2152. doi: 10.1001/jama.2017.17222.
Source | Full text | Similar articles

.

Nyame YA, Almassi N, Haywood SC, Greene DJ, Ganesan V, Dai C, Zabell J, Reichard C, Arora H, Zampini A, Crane A, Hettel D, Elshafei A, Fareed K, Stein RJ, Berglund RK, Gong M, Jones JS, Klein EA, Stephenson AJ.
Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
J Urol. 2017 Sep;198(3):591-599. doi: 10.1016/j.juro.2017.03.123. Epub 2017 Mar 24.
Source | Full text | Similar articles

.

Stöckle M.
[Is there still a role for active surveillance in prostate cancer?]
Urologe. 2017 May 17. doi: 10.1007/s00120-017-0412-6. [Epub ahead of print] [Article in German]
Source | English abstract | Full text | Similar articles

.

Syed JS, Javier-Desloges J, Tatzel S, Bhagat A, Nguyen KA, Hwang K, Kim S, Sprenkle PC.
Current Management Strategy for Active Surveillance in Prostate Cancer.
Curr Oncol Rep. 2017 Feb;19(2):11. doi: 10.1007/s11912-017-0569-6.
Source | Full text | Similar articles

.

Witherspoon L, Breau RH, Lavallée LT.
Evidence-based approach to active surveillance of prostate cancer.
World J Urol. 2019 Feb 6. doi: 10.1007/s00345-019-02662-5. [Epub ahead of print]
Source | Full text | Similar articles

.

Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R.
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy.
Clin Cancer Res. 2012 Oct 1;18(19):5471-8. doi: 10.1158/1078-0432.CCR-12-1502. Epub 2012 Sep 24.
Source | Full text | Similar articles

LOW-RISK (OR FAVORABLE-RISK) PROSTATE CANCER

.

D'Amico AV.
Personalizing the Use of Active Surveillance As an Initial Approach for Men With Newly Diagnosed Prostate Cancer.
J Clin Oncol. 2015 Oct 20;33(30):3365-6. doi: 10.1200/JCO.2015.63.6118. Epub 2015 Aug 31.
Source | Full text | Similar articles

.

Klotz L.
Active surveillance for low-risk prostate cancer.
Curr Opin Urol. 2017 Mar 4. doi: 10.1097/MOU.0000000000000393.
Source | Full text | Similar articles

.

Klotz L.
Active surveillance for low-risk prostate cancer.
Curr Urol Rep. 2015 Apr;16(4):24. doi: 10.1007/s11934-015-0492-z. Epub 2015 March 13.
Source | Full text | Similar articles

.

Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB.
Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.
J Clin Oncol. 2015 Oct 20;33(30):3379-85. doi: 10.1200/JCO.2015.62.5764. Epub 2015 Aug 31.
Source | Full text | Similar articles

.

Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB.
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
J Clin Oncol. 2011 Jun 1;29(16):2185-90. doi: 10.1200/JCO.2010.32.8112. Epub 2011 Apr 4.
Source | Full text | Similar articles

MULTIPARAMETRIC MAGNETIC-RESONANCE TO CONFIRM ELIGIBILITY

.

Galgano SJ, Glaser ZA, Porter KK, Rais-Bahrami S.
Role of Prostate MRI in the Setting of Active Surveillance for Prostate Cancer.
Adv Exp Med Biol. 2018;1096:49-67. doi: 10.1007/978-3-319-99286-0_3. First Online: 16 October 2018
Source | Full text | Similar articles

.

Luzzago S, Musi G, Catellani M, Russo A, Di Trapani E, Mistretta FA, Bianchi R, Cozzi G, Conti A, Pricolo P, Ferro M, Matei DV, Mirone V, Petralia G, de Cobelli O.
Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
Urol Int. 2018 May 7:1-9. doi: 10.1159/000488772. [Epub ahead of print]
Source | Full text | Similar articles

IS AS AN APPROPRIATE APPROACH FOR 3+3?

.

Ghiasy S, Abedi AR, Moradi A, Hosseini SY, Karkan MF, Sadri G, Davari M.
Is active surveillance an appropriate approach to manage prostate cancer patients with Gleason Score 3+3 who met the criteria for active surveillance?
Turk J Urol. 2018 Nov 19:1-4. doi: 10.5152/tud.2018.72920. [Epub ahead of print]
Source | Full text | Similar articles

INTERMEDIATE-RISK PROSTATE CANCER

.

Butler SS, Mahal BA, Lamba N, Mossanen M, Martin NE, Mouw KW, Nguyen PL, Muralidhar V.
Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Cancer. 2019 May 31. doi: 10.1002/cncr.32202. [Epub ahead of print]
Source | Full text | Similar articles

Klotz L.
Active surveillance in intermediate risk prostate cancer.
BJU Int. 2019 Oct 24. doi: 10.1111/bju.14935. [Epub ahead of print]
Source . Similar articles

.

Klotz L.
Active Surveillance for Intermediate Risk Prostate Cancer.
Curr Urol Rep. 2017 Aug 11;18(10):80. doi: 10.1007/s11934-017-0726-3.
Source | Full text | Similar articles

.

Masic S, Washington SL 3rd, Carroll PR.
Management of intermediate-risk prostate cancer with active surveillance: never or sometimes?
Curr Opin Urol. 2017 May;27(3):231-237. doi: 10.1097/MOU.0000000000000387. Epub 2017 May 1.
Source | Full text | Similar articles

Gleason grade 3 + 4 = 7

.

Bhat A, Punnen S.
Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?
Oncology (Williston Park). 2019 Jun 19;33(6):235-6.
Source | Full text | Similar articles

.

Madueke I, Abern MR.
Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?
Oncology (Williston Park). 2019 Jun 19;33(6):235, 237-8, 242.
Source | Full text | Similar articles

**

Park J, Yoo S, Cho MC, Jeong CW, Ku JH, Kwak C, Kim HH, Jeong H.
Patients with Biopsy Gleason Score 3 + 4 Are Not Appropriate Candidates for Active Surveillance.
Urol Int. 2019 Nov 6:1-6. doi: 10.1159/000503888. [Epub ahead of print]
Source . Similar articles

.

Shangguan X, Dong B, Wang Y, Xu F, Shao X, Sha J, Zhu Y, Pan J, Xue W.
Management of prostate cancer patients with locally adverse pathologic features after radical prostatectomy: feasibility of active surveillance for cases with Gleason grade 3 + 4 = 7.
J Cancer Res Clin Oncol. 2016 Sep 20. [Epub ahead of print]
Source | Full text | Similar articles

Favorable intermediate-risk prostate cancer

.

Dall'Era MA, Klotz L.
Active surveillance for intermediate-risk prostate cancer.
Prostate Cancer Prostatic Dis. 2016 Nov 1. doi: 10.1038/pcan.2016.51. [Epub ahead of print]
Source | Full text | Similar articles

.

Du C, Chen H, Li C.
Re: Alessandro Morlacco, John C. Cheville, Laureano J. Rangel, Derek J. Gearman, R. Jeffrey Karnes. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-risk" Prostate Cancer: Implications for Active Surveillance. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.08.043.
Eur Urol. 2017 Feb 3. pii: S0302-2838(17)30065-9. doi: 10.1016/j.eururo.2017.01.040. [Epub ahead of print]
Source | Full text | Similar articles

.

Gandaglia G, Briganti A, Montorsi F.
Re: Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-risk Prostate Cancer.
Eur Urol. 2016 Feb;69(2):370. doi: 10.1016/j.eururo.2015.10.059.
Source | Full text | Similar articles

.

Morlacco A, Cheville JC, Rangel LJ, Gearman DJ, Jeffrey Karnes R.
Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Eur Urol. 2016 Aug 28. pii: S0302-2838(16)30511-5. doi: 10.1016/j.eururo.2016.08.043. [Epub ahead of print]
Source | Full text | Similar articles

.

Musunuru HB, Yamamoto T, Klotz L, Ghanem G, Mamedov A, Sethukavalan P, Jethava V, Jain S, Zhang L, Vesprini D, Loblaw A.
Active Surveillance in Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.
J Urol. 2016 Aug 26. pii: S0022-5347(16)31142-9. doi: 10.1016/j.juro.2016.06.102. [Epub ahead of print]
Source | Full text | Similar articles

.

Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.
Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.
JAMA Oncol. 2015 Jun;1(3):334-40. doi: 10.1001/jamaoncol.2014.284.
Source | Full text | Similar articles

.

Saad F.
Active Surveillance in Prostate Cancer: How Far Should We Go?
JAMA Oncol. 2015 Jun;1(3):340-1. doi: 10.1001/jamaoncol.2015.103.
Source | Full text | Similar articles

ACTIVE SURVEILLANCE IN YOUNGER MEN

.

Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR.
Active Surveillance in Younger Men With Prostate Cancer.
J Clin Oncol. 2017 Mar 27:JCO2016680058. doi: 10.1200/JCO.2016.68.0058. [Epub ahead of print]
Source | Full text | Similar articles

Super-active surveillance

.

Bloom JB, Gold SA, Hale GR, Rayn KN, Sabarwal VK, Bakhutashvili I, Valera V, Turkbey B, Pinto PA, Wood BJ.
"Super-active surveillance": MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer.
Gland Surg. 2018 Apr;7(2):166-187. doi: 10.21037/gs.2018.03.06.
Source | Full text | Similar articles

.

Ghodoussipour S, Lebastchi AH, Bloom JB, Pinto PA, Berger A.
Super active surveillance for low-risk prostate cancer | Opinion: No.
Int Braz J Urol. 2019 Mar-Apr;45(2):215-219. doi: 10.1590/S1677-5538.IBJU.2019.02.03.
Source | Full text | Similar articles

.

Reis LO, Andrade DL, Bianco FJ Jr.
Super active surveillance for low-risk prostate cancer | Opinion: Yes.
Int Braz J Urol. 2019 Mar-Apr;45(2):210-214. doi: 10.1590/S1677-5538.IBJU.2019.02.02. Epub 2019 Mar 22.
Source | Full text | Similar articles

MUTATION STATUS OF BRCA1/2 AND ATM CAN HELP INFORM DECISIONS BETWEEN AS AND CURATIVE INTERVENTION

.

Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, Isaacs WB, Xu J.
Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
Eur Urol. 2018 Oct 8. pii: S0302-2838(18)30684-5. doi: 10.1016/j.eururo.2018.09.021. [Epub ahead of print]
Source | Full text | Similar articles

.

Roobol MJ.
Active Surveillance for Low-risk Prostate Cancer: Will it Become Obsolete?
Eur Urol. 2018 Oct 25. pii: S0302-2838(18)30809-1. doi: 10.1016/j.eururo.2018.10.021. [Epub ahead of print]
Editorial relating to: Carter HB et al, Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Eur Urol. 2018 Oct 8. pii: S0302-2838(18)30684-5. doi: 10.1016/j.eururo.2018.09.021. [Epub ahead of print]
Source | Full text | Similar articles